← Back to Analyst Consensus 
QTTB Buy
Q32 Bio Inc.
Current Price —
Implied Upside —
Analysts 13
30-Day Momentum
▲ 2 upgrades / ▼ 0 downgrades / 0 reiterations from 2 firms
Next Earnings
Nov 5, 2026 (10 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 12, 2026 | Leerink Partners | initiate | — → Outperform | — | 50% |
| Sep 28, 2026 | Jefferies | initiate | — → Buy | — | 52% |
| Aug 24, 2026 | Morgan Stanley | initiate | — → Overweight | — | 54% |
| Jul 28, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jul 13, 2026 | Oppenheimer | maintain | Outperform → Outperform | — | 52% |
| Jul 13, 2026 | Wells Fargo | upgrade | Equal-Weight → Overweight | — | 54% |
| May 22, 2026 | Mizuho | initiate | — → Outperform | — | 52% |
| May 18, 2026 | Cantor Fitzgerald | initiate | — → Overweight | — | 50% |
| May 5, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Feb 25, 2026 | HC Wainwright & Co. | initiate | — → Buy | $13 | 44% |
| Mar 12, 2025 | Wells Fargo | maintain | Equal-Weight → Equal-Weight | $15 | 54% |
| Feb 11, 2025 | BMO Capital | downgrade | Outperform → Market Perform | $3 | 53% |
| Feb 11, 2025 | Piper Sandler | downgrade | Overweight → Neutral | $4 | 54% |
| Dec 12, 2024 | BMO Capital | maintain | Outperform → Outperform | $22 | 53% |
| Dec 12, 2024 | Guggenheim | downgrade | Buy → Neutral | $0 | 52% |
| Dec 11, 2024 | Oppenheimer | maintain | Outperform → Outperform | $20 | 52% |
| Dec 11, 2024 | Piper Sandler | maintain | Overweight → Overweight | $20 | 54% |
| Dec 11, 2024 | Wells Fargo | downgrade | Overweight → Equal-Weight | $16 | 54% |
| Dec 11, 2024 | Leerink Partners | downgrade | Outperform → Market Perform | $9 | 50% |
| Dec 11, 2024 | Raymond James | downgrade | Strong Buy → Outperform | $22 | 54% |
| Dec 6, 2024 | BMO Capital | initiate | — → Outperform | $64 | 53% |
| Oct 24, 2024 | Raymond James | initiate | — → Strong Buy | $90 | 54% |
| Sep 11, 2024 | Wells Fargo | initiate | — → Overweight | $95 | 54% |
| Jun 17, 2024 | Guggenheim | initiate | — → Buy | $100 | 52% |
| May 21, 2024 | Leerink Partners | initiate | — → Outperform | $54 | 50% |
| Apr 11, 2024 | Oppenheimer | initiate | — → Outperform | $50 | 52% |
| Apr 2, 2024 | Piper Sandler | initiate | — → Overweight | $45 | 54% |
Price Target Trend
Jun 28, 2026 Oct 26, 2026
EPS Estimates
0q —
+1q —
0y —
+1y —
Cross-Platform Signals
No cross-platform signals in the last 90 days